Click here to registerSAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc.(NASDAQ:JAGX)Participation Instructions for WebcastWhen: Friday, April 10, 2026 at 8:30 a.m. EasternParticipant Registration

<p><a rel="nofollow" href="https://viavid.webcasts.com/starthere.jsp?ei=1754198&tp_key=0596f2aba1"><i><strong>Click here</strong></i></a><i><strong> to register</strong></i></p><p><strong id="dateline">SAN FRANCISCO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 9, 2026 / </strong><a rel="nofollow" href="https://pr.report/kjq7">Jaguar Health, Inc.</a><a rel="nofollow" href="https://pr.report/kjq8">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/JAGX">JAGX</a>)</a></p><p><strong>Participation Instructions for Webcast</strong></p><p>When: Friday, April 10, 2026 at 8:30 a.m. Eastern</p><p>Participant Registration & Access Link: <a rel="nofollow" href="https://pr.report/kjq9"><strong>Click Here</strong></a></p><p><strong>Replay Instructions for Webcast</strong></p><p>Replay of the webcast on the investor relations section of Jaguar's website: (<a rel="nofollow" href="https://pr.report/kjqa">click here</a>)</p><p><strong>About the Jaguar Health Family of Companies</strong></p><p>Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a rel="nofollow" href="https://pr.report/kjqb">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.</p><p><strong>For more information about:</strong></p><p>Jaguar Health, visit <a rel="nofollow" href="https://pr.report/kjqc">https://jaguar.health</a></p><p>Napo Therapeutics, visit <a rel="nofollow" href="https://pr.report/kjqd">napotherapeutics.com</a></p><p>Magdalena Biosciences, visit <a rel="nofollow" href="https://pr.report/kjqe">magdalenabiosciences.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will hold an investor webcast on April 1, 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p><strong>Contact:</strong></p><p><a rel="nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a><br/>Jaguar-JAGX</p><p><strong>SOURCE: </strong>Jaguar Health, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/reminder-jaguar-health-to-host-investor-webcast-at-8-30-am-eastern-on-1156553'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1156553" width="0" height="0"/>

JAGX

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Jaguar Health to Hold Key Investor Webcast on April 10, 2026

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Click here to registerSAN FRANCISCO, CA / ACCESS Newswire / April 9, 2026 / Jaguar Health, Inc.(NASDAQ:JAGX)Participation Instructions for WebcastWhen: Friday, April 10, 2026 at 8:30 a.m. EasternParticipant Registration</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Jaguar Health, Inc. will host an investor webcast on April 10, 2026, focusing on its innovative drug developments for gastrointestinal and mental health issues. This event is an important opportunity for investors to understand the company&#039;s future growth trajectory and potential market impact.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Jaguar Health is hosting an investor webcast on April 10, 2026.</li><li>The company develops novel medications for gastrointestinal disorders and mental health.</li><li>Webcast is crucial for stakeholders to gauge future growth and directions.</li><li>Investors will have access to live and replay options for the webcast.</li><li>Jaguar&#039;s ongoing product development could enhance its market presence.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Napo Pharmaceuticals, Inc. (N/A)</strong>: Focused on treatments for orphan GI disorders, enhancing product portfolio.</li><li><strong>Magdalena Biosciences (N/A)</strong>: Joint venture developing mental health treatments could expand market reach.</li><li><strong>Filament Health Corp. (N/A)</strong>: Collaborative efforts may lead to innovative psychiatric medicine solutions.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it relates directly to an upcoming investor event, which could impact valuation and investor sentiment significantly based on the insights provided during the webcast.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Upcoming webcast may provide critical insights into product pipeline and financials.</li><li>Positive investor sentiment could drive JAGX stock price higher post-webcast.</li><li>Details on clinical trials could significantly affect future valuation.</li><li>Partnership developments in mental health could unlock new revenue streams.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Webcast scheduled for April 10, 2026, at 8:30 a.m. Eastern.</li><li>Jaguar specializes in drugs for gastrointestinal diseases and mental health.</li><li>Napo Pharmaceuticals and Magdalena Biosciences are subsidiaries of Jaguar.</li><li>Webcast replay available on Jaguar&#039;s investor relations website.</li><li>Current market focus includes crofelemer for rare gastrointestinal disorders.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in JAGX ahead of the webcast for potential upward movement in stock value.</p>
  </section>
</section>


<p><a rel="nofollow" href="https://viavid.webcasts.com/starthere.jsp?ei=1754198&tp_key=0596f2aba1"><i><strong>Click here</strong></i></a><i><strong> to register</strong></i></p><p><strong id="dateline">SAN FRANCISCO, CA / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / April 9, 2026 / </strong><a rel="nofollow" href="https://pr.report/kjq7">Jaguar Health, Inc.</a><a rel="nofollow" href="https://pr.report/kjq8">(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/JAGX">JAGX</a>)</a></p><p><strong>Participation Instructions for Webcast</strong></p><p>When: Friday, April 10, 2026 at 8:30 a.m. Eastern</p><p>Participant Registration & Access Link: <a rel="nofollow" href="https://pr.report/kjq9"><strong>Click Here</strong></a></p><p><strong>Replay Instructions for Webcast</strong></p><p>Replay of the webcast on the investor relations section of Jaguar's website: (<a rel="nofollow" href="https://pr.report/kjqa">click here</a>)</p><p><strong>About the Jaguar Health Family of Companies</strong></p><p>Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's <a rel="nofollow" href="https://pr.report/kjqb">Entheogen Therapeutics Initiative</a> (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.</p><p><strong>For more information about:</strong></p><p>Jaguar Health, visit <a rel="nofollow" href="https://pr.report/kjqc">https://jaguar.health</a></p><p>Napo Therapeutics, visit <a rel="nofollow" href="https://pr.report/kjqd">napotherapeutics.com</a></p><p>Magdalena Biosciences, visit <a rel="nofollow" href="https://pr.report/kjqe">magdalenabiosciences.com</a></p><p><strong>Forward-Looking Statements</strong></p><p>Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that it will hold an investor webcast on April 1, 2026. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties, and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p><p><strong>Contact:</strong></p><p><a rel="nofollow" href="mailto:hello@jaguar.health">hello@jaguar.health</a><br/>Jaguar-JAGX</p><p><strong>SOURCE: </strong>Jaguar Health, Inc.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/reminder-jaguar-health-to-host-investor-webcast-at-8-30-am-eastern-on-1156553'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1156553" width="0" height="0"/>

Jaguar Health, Inc. will host an investor webcast on April 10, 2026, focusing on its innovative drug developments for gastrointestinal and mental health issues. This event is an important opportunity for investors to understand the company's future growth trajectory and potential market impact.

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News